Back to Search Start Over

Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.

Authors :
DelRocco NJ
Loh ML
Borowitz MJ
Gupta S
Rabin KR
Zweidler-McKay P
Maloney KW
Mattano LA
Larsen E
Angiolillo A
Schore RJ
Burke MJ
Salzer WL
Wood BL
Carroll AJ
Heerema NA
Reshmi SC
Gastier-Foster JM
Harvey R
Chen IM
Roberts KG
Mullighan CG
Willman C
Winick N
Carroll WL
Rau RE
Teachey DT
Hunger SP
Raetz EA
Devidas M
Kairalla JA
Source :
Leukemia [Leukemia] 2024 Apr; Vol. 38 (4), pp. 720-728. Date of Electronic Publication: 2024 Feb 15.
Publication Year :
2024

Abstract

Current strategies to treat pediatric acute lymphoblastic leukemia rely on risk stratification algorithms using categorical data. We investigated whether using continuous variables assigned different weights would improve risk stratification. We developed and validated a multivariable Cox model for relapse-free survival (RFS) using information from 21199 patients. We constructed risk groups by identifying cutoffs of the COG Prognostic Index (PI <subscript>COG</subscript> ) that maximized discrimination of the predictive model. Patients with higher PI <subscript>COG</subscript> have higher predicted relapse risk. The PI <subscript>COG</subscript> reliably discriminates patients with low vs. high relapse risk. For those with moderate relapse risk using current COG risk classification, the PI <subscript>COG</subscript> identifies subgroups with varying 5-year RFS. Among current COG standard-risk average patients, PI <subscript>COG</subscript> identifies low and intermediate risk groups with 96% and 90% RFS, respectively. Similarly, amongst current COG high-risk patients, PI <subscript>COG</subscript> identifies four groups ranging from 96% to 66% RFS, providing additional discrimination for future treatment stratification. When coupled with traditional algorithms, the novel PI <subscript>COG</subscript> can more accurately risk stratify patients, identifying groups with better outcomes who may benefit from less intensive therapy, and those who have high relapse risk needing innovative approaches for cure.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1476-5551
Volume :
38
Issue :
4
Database :
MEDLINE
Journal :
Leukemia
Publication Type :
Academic Journal
Accession number :
38360863
Full Text :
https://doi.org/10.1038/s41375-024-02166-1